12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral GCD: Phase I started

Protalix began an open-label, Israeli Phase I trial to evaluate 4 doses of oral PRX-112 in about 12...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >